Crohn's disease

Patients with Crohn's reported more relapses and are more likely to see diet as a relapse trigger; nutritional therapy (including elemental diets) is used more often in Crohn's than UC in this Japanese sample. This...

Some rare appendiceal cancers can present like treatment-resistant Crohn’s disease. Considering malignancy is important when ileocecal strictures persist despite dilation and biopsies are negative.

The article connects everyday activities like gardening and spending time in nature to microbial exposure that some researchers link to lower rates of autoimmune and inflammatory conditions, including Crohn’s disease and...

Vitamin D may support intestinal barrier integrity and immune regulation—pathways central to mucosal healing and disease control in IBD. Understanding the evidence helps patients and clinicians consider vitamin D as a...

Frequent, accurate assessment of bowel inflammation and fibrosis is critical for Crohn's disease care. Ultrasound is safe, accessible, and could provide a low-cost biomarker to monitor disease activity, fibrosis, and...

Injection site pain and local reactions can affect comfort and willingness to continue injectable biologic therapy.

People with both IBD and another immune-mediated disease (psoriatic disease) had more hospital admissions and higher inpatient costs over ten years in this population.

SpA is a frequent but underrecognized extraintestinal manifestation in people with IBD; validated screening tools can help identify patients who need rheumatology evaluation. Earlier detection may address joint symptoms...

Oral problems and periodontal disease can affect quality of life and may be more common in people with IBD; this study suggests many patients report oral health needs and gaps in dental care.

A well-known athlete describing recovery from major Crohn’s-related surgery may offer perspective and hope to people living with the condition and to families of young athletes facing serious illness. His new coaching...

Perianal fistulas in Crohn’s disease are hard to treat and preserving continence is important. Long-term data suggesting laser ablation can achieve sustained healing in some patients are relevant for treatment decisions.

The study highlights factors linked to needing another operation after ileocecal resection for Crohn’s disease and suggests postoperative biologic therapy may lower long-term reoperation risk. That directly affects...

Microbial changes after ileocecal resection appear linked to the degree of postoperative inflammation; understanding these changes could help predict or prevent Crohn’s recurrence after surgery.

People with Crohn’s may be interested because the review discusses novel natural compounds that target oxidative stress and inflammation — pathways involved in disease activity — and highlights formulation challenges...

The study provides real-world effectiveness and safety data for risankizumab in a largely difficult-to-treat Crohn's population, showing about half achieved corticosteroid-free clinical remission at 24 weeks —...

This helps people with IBD and their care teams make delivery plans: if perianal disease is not active, having IBD alone was not linked to higher perineal injury risk in first-time vaginal births in this study.

The oral microbiome in children with Crohn's disease appears to reflect disease severity and changes with treatment, suggesting a potential noninvasive biomarker for monitoring response to nutritional therapies like CDED...

Adding partial enteral nutrition to ustekinumab was associated with better clinical, endoscopic, radiologic, and nutritional outcomes at 52 weeks in this multicentre real-world cohort of Crohn’s disease patients. This...

Researchers identified a strain-variable adhesin (Hil1) in the food-associated yeast Debaryomyces hansenii that affects adhesion and is recognized by antibodies from Crohn disease patients.

This study suggests that genetic risk for Crohn disease and ulcerative colitis may causally increase the risk of developing ankylosing spondylitis, an inflammatory joint condition that commonly co-occurs with IBD.

If true, a causal link between IBD and pancreatitis could help explain why people with Crohn’s disease or ulcerative colitis sometimes develop acute or chronic pancreatitis and could guide research into shared biological...

This study suggests adults with moderate-to-severe atopic dermatitis may have a higher-than-expected prevalence of IBD compared with general population estimates, and AD often precedes IBD—so dermatologists and patients...

This preclinical study suggests cigarette smoke alters gut microbes and metabolites in ways that can either protect or worsen colitis depending on the model; it identifies 4-HBA as a metabolite that reduced inflammation...

Frailty is linked to worse outcomes in older people with IBD, so knowing how common it is—and which patients are at higher risk—can influence monitoring and treatment planning.

Shows which IBD comorbidities may be driven in part by shared inherited genetic risk and which likely reflect non-genetic factors, information that could shape future risk stratification and screening approaches for...

Combination (dual) therapy is an active area of research because many people with Crohn’s disease don’t achieve lasting remission on a single advanced therapy. New trials suggest some combinations may improve remission...

Market shifts — including more biosimilars, expanding biologic and small-molecule options, and wider online pharmacy access — can affect how quickly and affordably new Crohn’s treatments reach patients. Patients on...

People with IBD commonly have extraintestinal symptoms (mood disorders, fatigue, pain, nutritional problems) that affect quality of life and need proactive identification and management in primary care.

This trial could provide long-term safety data on guselkumab for children with moderate-to-severe Crohn's disease or ulcerative colitis and offers continued access to the drug for participants from earlier pediatric...

The study explores engineering HSPCs to induce IL-10–mediated, antigen-specific regulatory responses, which could lead to new cell-based strategies for children with refractory IBD who do not respond to current...

People with IBD sometimes are excluded from or uncertain about immune checkpoint inhibitor cancer trials because of concerns about triggering autoimmune flares. This trial explicitly studies safety and disease impact in...

A Phase 3 trial is testing whether guselkumab can produce MRI-detected transmural healing in Crohn's disease — an outcome that could reflect deeper intestinal healing than symptom improvement alone. If successful, it may...

A large network meta-analysis found adalimumab reduces risk of clinical relapse in Crohn’s disease and upadacitinib reduces loss of clinical response; these findings summarize comparative maintenance therapy evidence...

Based on the title and source metadata, this appears to be an observational study related to Crohn's disease, Inflammatory bowel disease, and Research and clinical trials. The original article is from cureus.com.

Based on the title and source metadata, this appears to be a case report related to Crohn's disease, Stricture, and Procedures and surgery. The original article is from United European Gastroenterology Journal.

People with IBD who are breastfeeding and are taking guselkumab may want data on how much of the drug gets into breast milk and the estimated infant exposure. This study aims to provide those measurements for the Q4W and...

This Phase 3 trial directly compares two IL-23–targeting biologic therapies in moderate-to-severe Crohn's disease with a 52-week deep remission endpoint, which could inform future treatment choices if results are...

This registry will collect one-year, patient-reported outcomes on symptom control and clinical remission while people with IBD receive Zymfentra (infliximab-dyyb) in routine care — information that may help patients and...

New oral therapies in Phase 2/3 could expand treatment options for adults with moderate–severe Crohn's disease, including those who are naïve to advanced therapies or who failed prior biologics.

This trial tests whether pomegranate juice can lower fecal calprotectin, a commonly used marker of intestinal inflammation, in people with IBD in remission. If effective, such a dietary approach could be of interest to...

Accepted applications for a vedolizumab biosimilar could lead to another treatment option for adults with moderate‑to‑severe ulcerative colitis and Crohn’s disease and may improve access or affordability if approved.

The study suggests why a JAK1 inhibitor (filgotinib) may work better in some gut regions than others, offering a possible explanation for mixed clinical trial results in Crohn's disease. This could influence how future...

If approved, a vedolizumab biosimilar could increase access to an established IBD biologic by offering a lower-cost alternative, potentially reducing barriers to starting or continuing treatment for people with...

An updated FDA drug label affects how ustekinumab is prescribed and monitored. It confirms Crohn’s disease and ulcerative colitis as approved uses and highlights safety concerns (infections, TB screening, malignancy)...

HLH is a rare but life‑threatening complication that can be triggered by herpesvirus infection in immunosuppressed IBD patients. Awareness may speed diagnosis and treatment for symptomatic patients on therapies like JAK...

Disability related to IBD affects daily functioning and quality of life; identifying factors linked with higher or lower disability (vitamin D status, azathioprine use, smoking) can help patients and clinicians consider...

CDI occurs more often in hospitalized people with IBD than in those without IBD. Understanding which patients are at higher risk for death or complications can help hospitals prioritize early testing and management to...

PROM completion is important for monitoring symptoms and disease control between visits. The study shows a single empowerment campaign produced a short‑term boost in PROM response but not sustained engagement,...